SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

Business
Money on the Move: April 14-20
Investment funds continue springing up into life sciences companies across the globe. Here’s where the money’s being planted this week.
April 20, 2021
 · 
4 min read
 · 
Kate Goodwin
The Column Group Debuts $824 Million Biotech Crossover Fund
Science-driven VC firm The Column Group set up its debut crossover fund with an oversubscribed $824 million to start.
April 20, 2021
 · 
2 min read
 · 
Kate Goodwin
Policy
Anixa Hits FDA Speedbump for Ovarian Cancer CAR-T Trial Approval
The government agency is asking for more information before approving a clinical study on the company’s Chimeric Antigen Receptor-T cell therapy (CAR-T).
April 19, 2021
 · 
2 min read
 · 
Kate Goodwin
Policy
Pacira Takes ASA to Court in Defense of Non-Opioid Painkiller
With its only approved drug product on the line, Pacira Biosciences is fighting back against what it’s calling “misrepresentation of the clinical effectiveness” of its non-opioid pain reliever Exparel.
April 16, 2021
 · 
3 min read
 · 
Kate Goodwin
Tada Images/Shutterstock
Deals
Thermo Fisher Drops $17.4 Billion to Buy a Popular CRO
The medical device maker has been dropping money like rain this spring, spending close to $19 billion in acquisitions over the past four months.
April 15, 2021
 · 
2 min read
 · 
Kate Goodwin
Michel Stoupak/NurPhoto via Getty Images
Business
Sanofi Continues Site Expansions, Preparing for Future Pandemics
The new factory will include cutting-edge technology, allowing production of three to four vaccines simultaneously, a massive improvement on the current limitation of one vaccine in an industrial site.
April 12, 2021
 · 
2 min read
 · 
Kate Goodwin
How a Common Cold Virus is Helping Fight Cancer
While a failed ebola drug helped treat hospitalized COVID-19 patients, the common cold virus could become key in treating advanced unresectable cancers.
April 9, 2021
 · 
2 min read
 · 
Kate Goodwin
Marcelo Bigal, CEO of Ventus.
Business
Ventus Scoops Up $100 Million to Take NLRP3 Inhibitor to the Clinic
Eleven months after launching with $60 million in hand, Ventus Therapeutics has raised another $100 million to drive its pipeline toward the clinic.
April 8, 2021
 · 
2 min read
 · 
Kate Goodwin
Deals
Money on the Move: March 31 – April 6
April springs up with showers of cash for these life sciences companies.
April 6, 2021
 · 
4 min read
 · 
Kate Goodwin
Gilead Sciences CEO Daniel O’Day (Gilead)
Business
Gilead CEO Got $19 Million Pay in Blockbuster Year for Company
Gilead CEO Daniel O’Day navigated the company through the turbulent waters of COVID-19 last year, pushing out the very first approved treatment for treatment of the virus. His reward? A $19 million take home.
April 6, 2021
 · 
2 min read
 · 
Kate Goodwin
Business
Iveric Bio’s Co-Founder Leaves to Return to Venture Capitalist Role
He’ll make a return to his former role at SV Health Investors as a Venture Partner.
April 5, 2021
 · 
1 min read
 · 
Kate Goodwin
Business
Can You Spread COVID-19 Once Vaccinated? Data Not Yet Clear
If you’re one of the 17% of Americans that have been fully vaccinated against SARS-CoV-2, you are probably feeling some level of relief. But the CDC warns not to throw your mask away just yet.
April 2, 2021
 · 
3 min read
 · 
Kate Goodwin
Deals
Eloxx Acquires Zikani with Hopes to Rule the RNA Wave for Rare Disease
Eloxx Pharma has experienced a string of changes over the past year, coming to a head with today’s announcement that the company will be acquiring early-stage biotech Zikani Therapeutics in an all-stock deal.
April 1, 2021
 · 
3 min read
 · 
Kate Goodwin
Business
Money on the Move: March 24-30
Over $700 million dropped into IPO biotech stock this week, with hundreds of millions more pouring into company financing rounds. Here are some of the top earners this past week.
March 30, 2021
 · 
5 min read
 · 
Kate Goodwin
Drug Development
Zero to Hero – Tainted Company Bounces Back with Successful COVID-19 Drug
Humanigen, the biotech briefly run by “Pharma Bro” Martin Shkreli under the name KaloBios up until his arrest, is back in the game with an antibody that is keeping COVID-19 patients off of ventilators and improving survival.
March 29, 2021
 · 
2 min read
 · 
Kate Goodwin
Load More